Search

Search results

722 results found

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.

Kimball, Alexa B, Kenneth B Gordon, Richard G Langley, Alan Menter, Elliot K Chartash, Joaquin Valdes, and ABT-874 Psoriasis Study Investigators. 2008. “Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial.”. Archives of Dermatology 144 (2): 200-7.

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.

Kimball, Alexa B, Kenneth B Gordon, Richard G Langley, Alan Menter, Renee J Perdok, Joaquin Valdes, and ABT-874 Study Investigators. 2011. “Efficacy and Safety of ABT-874, a Monoclonal Anti-Interleukin 12/23 Antibody, for the Treatment of Chronic Plaque Psoriasis: 36-Week Observation/Retreatment and 60-Week Open-Label Extension Phases of a Randomized Phase II Trial.”. Journal of the American Academy of Dermatology 64 (2): 263-74.